Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
News Archive
News Archive Navigation
News Archive Navigation Language
August 2024
-
Reference Validation
-
Reference 1
-
Content synch validation - end to end
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus
-
Story for refrence with : reference
-
Story validation of reference
-
Story for refrence
-
image alignments with all Alignments
-
Pulse Update
Title and Alt
Specify an alternative path by which this data can be accessed. For example, type "/about" when writing an about page.Specify an alternative path by which this data can be accessed. For example, type "/about" when writing an about page.Specify an alternative path by which this data can be accessed. For example, type "/about" when writing an about page.
-
Featured News
Dummy Featured News
-
Lorem Ipsum
July 2024
-
Media Release
Novartis Scemblix® granted FDA Priority Review for the treatment of adults with newly diagnosed CML
Priority Review based on ASC4FIRST Phase III study with Scemblix® data first to show significantly improved molecular response and a favorable safety and tolerability profile compared to standard of… -
Featured News
Novartis Financial Results – Q2 2024
Novartis announced the company’s financial results for the second quarter and first half of 2024.
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- …
- 154
- › Next page
Test disclaimer...!!!